Robert Davis

Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure

D. Kass, T. Povsic, V. Hahn, 2021, Circulation. Heart failure.

Cardiac and Hemodynamic Effects of Acute Phosphodiesterase-1 Inhibition in Human Heart Failure

D. Kass, T. Povsic, V. Hahn, 2020 .

ITI-214, A Novel Phosphodiesterase I Inhibitor for the Treatment of Parkinson’s Disease: Results from A Phase I/II Clinical Study (P2.8-051)

G. Snyder, J. Hendrick, L. Wennogle, 2019 .

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA

C. Correll, A. Dmitrienko, A. Satlin, 2018, Schizophrenia Bulletin.

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials

J. Kane, S. Durgam, A. Satlin, 2021, International clinical psychopharmacology.

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats

G. Snyder, J. Hendrick, Hongwen Zhu, 2016, Psychopharmacology.

S117. FAVORABLE LONG-TERM SAFETY PROFILE OF LUMATEPERONE IITI-007): RESULTS FROM A 12 MONTH OPEN LABEL SAFETY STUDY FOR LUMATEPERONE IN PATIENTS WITH STABLE SYMPTOMS OF SCHIZOPHRENIA

A. Satlin, K. Vanover, S. Mates, 2019, Schizophrenia Bulletin.

S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY

C. Correll, A. Dmitrienko, A. Satlin, 2018, Schizophrenia Bulletin.